9:20am ET
Health and Healthcare
Short Sellers Remain Vigilant Against Biotechs
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the latest report.
Companies
/Healthcare
Mannkind Corp
$3.95
▼ $0.11 (−2.71%) today
Markets closed · 9:23am ET
MNKD Coverage
Page 17
10:25am ET
Health and Healthcare
Rising Short Interest in Biotech Stocks
Short sellers might be inclined to bet against biotech companies because of their volatile behavior on the charts.
9:53am ET
Health and Healthcare
What the Market Is Telling MannKind (Updated)
MannKind Corp. (NASDAQ: MNKD) was supposed to be a huge winner on this week’s news that Sanofi (NYSE: SNY) will become its global partner for its inhalable insulin Afrezza. There has been just one…
9:11am ET
Health and Healthcare
MannKind Secures Future of Afrezza in Major Sanofi Deal
ThinkstockMannKind Corp. (NASDAQ: MNKD) was supposed to be in the news for its earnings report. Instead, we got news of its strategy on how to get its Afrezza inhalable insulin to the…
9:20am ET
Investing
Thirteen Analyst Stocks Under $10 With Huge Upside Potential
ThinkstockStocks hit a new all-time this last week on the heels of a strong unemployment and jobs number. Now investors have to decide whether the next year or more will simply be…
Jon C. Ogg 11:55am ET
Health and Healthcare
MannKind Poll Points to Bias That Stock Will Rise Above $15 into 2015
24/7 Wall St. ran a poll for investors this week on where MannKind shares would go into 2015, and the results were overwhelmingly bullish.
Jon C. Ogg 8:55am ET
Investing
Top Analyst Upgrades and Downgrades: Juniper Networks, Netflix, MannKind, Xerox and More
These are the top analyst upgrades, downgrades and initiations from Wall Street firms on Tuesday, July 1. They include Amicus Therapeutics, Juniper Networks, Netflix, MannKind and Xerox.
2:30pm ET
Health and Healthcare
Poll: Where Does MannKind Stock Go in 2015 After Afrezza Approval?
ThinkstockMannKind Corp. (NASDAQ: MNKD) has seen its shares surge on news that it has finally won U.S. Food & Drug Administration backing. This FDA approval for Type 1 and 2 diabetes is…
Jon C. Ogg 10:30am ET
Health and Healthcare
Vindication for MannKind on FDA Approval
After markets closed last Friday, MannKind announced that the FDA had approved Afrezza, a rapid-acting, inhaled insulin powder that improves glycemic control in adults with diabetes.
Paul Ausick 4:47pm ET
Health and Healthcare
MannKind’s Afrezza Inhaled Insulin Drug Gets FDA Approval
ThinkstockThe U.S. Food and Drug Administration (FDA) late Friday afternoon announced that it has approved Afrezza, a rapid-acting, inhaled insulin power that improves glycemic control in adults with diabetes. The FDA estimates…
Paul Ausick 11:10am ET
Investing
Twelve Analyst Stocks Trading Under $10 With Huge Implied Upside
ThinkstockStocks have pulled back from their all-time highs after escalation of civil war in Iraq, but Friday managed to close higher. Investors remain bullish, and they keep hearing that the bull market…
9:20am ET
Health and Healthcare
The MannKind Lifeline Lights Up
MannKind is just about a month away from the FDA decision on Afrezza as the first inhalable insulin treatment for diabetes. Afrezza almost certainly will become a blockbuster drug if approved.
Jon C. Ogg 8:30am ET
Investing
Top Analyst Upgrades and Downgrades: Alcoa, Intel, Lululemon, MannKind, Marathon, Occidental and More
These are the top Wall Street analyst upgrades, downgrades and initiations for Friday, June 13, 2014. They include Alcoa, Intel, Lululemon, MannKind, Marathon and Occidental Petroleum.
6:50am ET
Health and Healthcare
Short Sellers Remain Vigilant Against Top Biotech Stocks
ThinkstockShort sellers have many reasons to bet against a stock, some of which are hedging or part of a larger theme. Other reasons may be a bet against a company or sector,…
9:10am ET
Investing
Twelve Analyst Stocks to Buy Under $10 for Big Upside
ThinkstockStocks hit new highs this past week, only to sell off handily. Investors want gains, but they remain wary. 24/7 Wall St. reviews dozens of analyst research reports from Wall Street and…